Welcome to our dedicated page for CytomX Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on CytomX Therapeutics stock.
CytomX Therapeutics develops oncology biologics built on its PROBODY therapeutic platform, which masks and conditionally activates antibody-based therapies in the tumor microenvironment. News about CTMX commonly covers clinical updates for varsetatug masetecan, or Varseta-M, an EpCAM PROBODY ADC studied in advanced colorectal cancer and other EpCAM-expressing tumors, as well as CX-801, a masked Interferon-alpha-2b program initially developed in advanced melanoma.
Company updates also address financial results, research and development spending, cash runway, equity financings, and collaboration activity with Amgen, Regeneron, and Moderna. Recurring pipeline coverage includes dose-expansion data, combination-study activity, regulatory interactions, and PROBODY platform applications such as bispecific immunotherapies and T-cell engagers.
CytomX Therapeutics (Nasdaq: CTMX) will report first quarter 2026 financial results on Thursday, May 7, 2026 after U.S. market close. The company will host a conference call and live webcast at 5:00 p.m. ET / 2:00 p.m. PT, with an archived replay available on its investor website.
CytomX (Nasdaq:CTMX) priced an underwritten public offering to raise approximately $250.0 million in gross proceeds by selling 45,990,567 shares of common stock at $5.30 per share and pre-funded warrants for 1,179,245 shares.
The company granted a 30-day option for an additional 7,075,471 shares and expects to close on March 19, 2026. Net proceeds are expected to fund continued development of Varseta-M and other pipeline programs, with remaining proceeds for capital expenditures, working capital and general corporate purposes.
CytomX Therapeutics (NASDAQ:CTMX) has commenced an underwritten public offering of $250.0 million of common stock and, for certain investors, pre-funded warrants, with a 30-day underwriter option to purchase up to an additional $37.5 million. The offering is subject to market and other conditions and may not be completed.
According to the company, net proceeds are expected to fund continued development of Varseta-M and other pipeline programs, with any remaining proceeds for capital expenditures, working capital and general corporate purposes. A shelf registration filed March 16, 2026, became effective upon filing.
CytomX (Nasdaq: CTMX) reported 2025 results and a business update on March 16, 2026. Key items: positive Phase 1 Varseta-M data in advanced colorectal cancer, FDA alignment targeted mid‑2026 for a registrational trial, initiated Varseta-M/bevacizumab combination, and CX‑801 combination data expected by end of 2026.
Financials: $137.1M cash at year‑end with runway to Q2 2027, 2025 revenue $76.2M (down from $138.1M), and 2025 operating expense $98.6M.
CytomX (Nasdaq: CTMX) reported positive Phase 1 expansion data for EpCAM PROBODY ADC varsetatug masetecan in late-line metastatic colorectal cancer. Confirmed ORRs were 32% at 10 mg/kg and 20% at 8.6 mg/kg; estimated median PFS was 7.1 and 6.8 months, respectively. Grade 3 diarrhea was 10% with updated prophylaxis. The company plans FDA interactions in mid-2026 and additional combination and expansion studies through 2026.
CytomX Therapeutics (Nasdaq: CTMX) will report full year 2025 financial results on March 16, 2026, before the open of U.S. markets. The company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT the same day.
Participants can access the live webcast and archived replay on CytomX's Events and Presentations page and are advised to register at least 10 minutes before the call.
CytomX Therapeutics (Nasdaq: CTMX) announced management will present at two investor conferences in February 2026: Guggenheim Emerging Outlook: Biotech Summit on Feb 11, 2026 (fireside chat at 4:30 p.m. ET) and World ADC London on Feb 25, 2026 (presentation at 5:00 p.m. GMT).
Investors can find schedules and webcast details on the company's Events and Presentations page.
CytomX (NASDAQ: CTMX) provided a 2026 business update focused on clinical milestones for its PROBODY pipeline. Varsetatug masetecan (CX-2051) Phase 1 dose expansions (7.2, 8.6, 10 mg/kg Q3W) continue, with total Phase 1 enrollment projected at ~100 patients and a Phase 1 CRC expansion update expected in Q1 2026. The company aims to align with the FDA in 2026 on a potential registrational monotherapy study and plans a Varseta-M plus bevacizumab combination study to start in Q1 2026.
CX-801 (masked interferon-alpha-2b) is in Phase 1 for advanced melanoma; monotherapy reached dose level 4 and combination dose escalation with KEYTRUDA began in May 2025, with initial combo data expected by end of 2026. Management will present at JP Morgan on January 14, 2026.
CytomX Therapeutics (NASDAQ: CTMX) announced management will present at two investor conferences in December 2025: the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 (fireside chat at 1:45 p.m. ET) in Coral Gables, FL, and the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 (fireside chat at 1:00 p.m. ET) in New York, NY.
A live webcast will be available on the company’s Events and Presentations page at www.cytomx.com, and management will hold one-on-one meetings with registered conference attendees.
CytomX Therapeutics (Nasdaq: CTMX) said Sean McCarthy, D.Phil., chief executive officer and chairman, will take part in a fireside chat at the Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025 at 9:00 a.m. GMT.
A live webcast will be available on the company’s Events and Presentations page at www.cytomx.com, and management will be available for one-on-one investor meetings for registered conference attendees.